83 related articles for article (PubMed ID: 25878563)
1. Cost-effectiveness analysis of the available pneumococcal conjugated vaccines for children under five years in Colombia.
Ordóñez JE; Orozco JJ
Cost Eff Resour Alloc; 2015; 13():6. PubMed ID: 25878563
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of PCV20 to Prevent Pneumococcal Disease in the Pediatric Population: A German Societal Perspective Analysis.
Ta A; Kühne F; Laurenz M; von Eiff C; Warren S; Perdrizet J
Infect Dis Ther; 2024 Jun; 13(6):1333-1358. PubMed ID: 38733494
[TBL] [Abstract][Full Text] [Related]
3. Estimating the Impact of Switching from a Lower to Higher Valent Pneumococcal Conjugate Vaccine in Colombia, Finland, and The Netherlands: A Cost-Effectiveness Analysis.
Pugh S; Wasserman M; Moffatt M; Marques S; Reyes JM; Prieto VA; Reijnders D; Rozenbaum MH; Laine J; Åhman H; Farkouh R
Infect Dis Ther; 2020 Jun; 9(2):305-324. PubMed ID: 32096144
[TBL] [Abstract][Full Text] [Related]
4. Towards the introduction of pneumococcal conjugate vaccines in Bhutan: A cost-utility analysis to determine the optimal policy option.
Dorji K; Phuntsho S; Pempa ; Kumluang S; Khuntha S; Kulpeng W; Rajbhandari S; Teerawattananon Y
Vaccine; 2018 Mar; 36(13):1757-1765. PubMed ID: 29478752
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of pneumococcal conjugate vaccine 13-valent in older adults in Colombia.
Ordóñez JE; Orozco JJ
BMC Infect Dis; 2014 Mar; 14():172. PubMed ID: 24679135
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of pediatric immunization program with 15-valent pneumococcal conjugate vaccine in Japan.
Tajima A; Abe M; Weaver J; Huang M
J Med Econ; 2023; 26(1):1034-1046. PubMed ID: 37555281
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of the pediatric 20-valent pneumococcal conjugate vaccine compared with lower-valent alternatives in Argentina.
Rey-Ares L; Ta A; Freigofaite D; Warren S; Mac Mullen M; Carballo C; Huang L
Vaccine; 2024 Jun; ():. PubMed ID: 38879409
[TBL] [Abstract][Full Text] [Related]
8. Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to Higher-Valent Options in Greek Infants.
Warren S; Barmpouni M; Kossyvaki V; Gourzoulidis G; Perdrizet J
Vaccines (Basel); 2023 Aug; 11(8):. PubMed ID: 37631937
[TBL] [Abstract][Full Text] [Related]
9. Potential cost-effectiveness and benefit-cost ratios of adult pneumococcal vaccination in Germany.
Kuhlmann A; Theidel U; Pletz MW; von der Schulenburg JM
Health Econ Rev; 2012 Mar; 2(1):4. PubMed ID: 22828176
[TBL] [Abstract][Full Text] [Related]
10. Evolution of Pneumococcal Vaccine Recommendations and Criteria for Decision Making in 5 Western European Countries and the United States.
Noharet-Koenig R; Lasota K; Faivre P; Langevin E
MDM Policy Pract; 2023; 8(1):23814683231174432. PubMed ID: 37274614
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness of the COVID-19 Test, Trace and Isolate Program in Colombia.
Guzmán Ruiz Y; Vecino-Ortiz AI; Guzman-Tordecilla N; Peñaloza-Quintero RE; Fernández-Niño JA; Rojas-Botero M; Ruiz Gomez F; Sullivan SD; Trujillo AJ
Lancet Reg Health Am; 2022 Feb; 6():100109. PubMed ID: 34755146
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of 10- and 13-valent pneumococcal conjugate vaccines in Peru.
Mezones-Holguin E; Canelo-Aybar C; Clark AD; Janusz CB; Jaúregui B; Escobedo-Palza S; Hernandez AV; Vega-Porras D; González M; Fiestas F; Toledo W; Michel F; Suárez VJ
Vaccine; 2015 May; 33 Suppl 1():A154-66. PubMed ID: 25919156
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of pneumococcal conjugate vaccine introduction in Paraguay.
Kieninger MP; Caballero EG; Sosa AA; Amarilla CT; Jáuregui B; Janusz CB; Clark AD; Castellanos RM
Vaccine; 2015 May; 33 Suppl 1():A143-53. PubMed ID: 25919155
[TBL] [Abstract][Full Text] [Related]
14. The serotype distribution among healthy carriers before vaccination is essential for predicting the impact of pneumococcal conjugate vaccine on invasive disease.
Flasche S; Le Polain de Waroux O; O'Brien KL; Edmunds WJ
PLoS Comput Biol; 2015 Apr; 11(4):e1004173. PubMed ID: 25879748
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada.
Deceuninck G; De Serres G; Boulianne N; Lefebvre B; De Wals P
Vaccine; 2015 May; 33(23):2684-9. PubMed ID: 25887086
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of pneumococcal conjugate vaccination in Georgia.
Komakhidze T; Hoestlandt C; Dolakidze T; Shakhnazarova M; Chlikadze R; Kopaleishvili N; Goginashvili K; Kherkheulidze M; Clark AD; Blau J
Vaccine; 2015 May; 33 Suppl 1():A219-26. PubMed ID: 25919165
[TBL] [Abstract][Full Text] [Related]
17. Recent Developments and Future Directions of Pneumococcal Vaccine Recommendations.
Tromp KM; Campbell MW; Vazquez A
Clin Ther; 2015 May; 37(5):928-34. PubMed ID: 25913921
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
[TBL] [Abstract][Full Text] [Related]
19. Invasive Pneumococcal Disease Following the Introduction of 13-Valent Conjugate Vaccine in Children in New York City From 2007 to 2012.
Farnham AC; Zimmerman CM; Papadouka V; Konty KJ; Zucker JR; Nattanmai GV; Jose S; Rosen JB
JAMA Pediatr; 2015 Jul; 169(7):646-52. PubMed ID: 25938798
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of the introduction of the pneumococcal conjugate vaccine (PCV-13) in the Egyptian national immunization program, 2013.
Sibak M; Moussa I; El-Tantawy N; Badr S; Chaudhri I; Allam E; Baxter L; Abo Freikha S; Hoestlandt C; Lara C; Hajjeh R; Munier A
Vaccine; 2015 May; 33 Suppl 1():A182-91. PubMed ID: 25919159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
